{
  "ticker": "LLY",
  "target_date": "2025-03-14",
  "actual_date": "2025-03-14",
  "collected_at": "2025-12-08T11:31:11.341937",
  "price": {
    "open": 798.54,
    "high": 810.57,
    "low": 795.45,
    "close": 808.8489379882812,
    "volume": 3102300,
    "change_1d_pct": 1.48,
    "change_7d_pct": -12.5,
    "change_30d_pct": -1.01
  },
  "technicals": {
    "rsi_14": 36.15,
    "sma_20": 869.17,
    "sma_50": 824.83,
    "macd": -4.004,
    "macd_signal": 10.969,
    "macd_histogram": -14.972,
    "bb_upper": 950.84,
    "bb_lower": 787.51,
    "price_vs_sma20_pct": -6.94,
    "price_vs_sma50_pct": -1.94,
    "volume_ratio": 0.84
  },
  "fundamentals": {
    "market_cap": 889742295040,
    "pe_ratio": 48.628613,
    "forward_pe": 43.80009,
    "price_to_book": 37.3686,
    "price_to_sales": 14.973835,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.74,
    "pct_from_52w_low": 59.11
  },
  "macro": {
    "spy": {
      "price": 557.92,
      "change_1d_pct": 2.07,
      "change_7d_pct": -1.73
    },
    "vix": {
      "level": 21.77,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.31
    },
    "dollar_index": {
      "level": 103.72
    },
    "gold": {
      "price": 2994.5
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "AstraZeneca Stock Scores RS Rating Upgrade",
      "source": "Yahoo",
      "datetime": 1741982520,
      "summary": "AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.",
      "url": "https://finnhub.io/api/news?id=a6bdc95763d16b3f6e8ac10b2bca3e91a0d4ed282d09b4845b98b90c25ca0d93"
    },
    {
      "headline": "Eli Lilly (NYSE:LLY) Sees 1.59% Rise As Jaypirca Secures Positive EU Opinion",
      "source": "Yahoo",
      "datetime": 1741974075,
      "summary": "Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in treating severe alopecia areata and long-term efficacy data for EBGLYSS in atopic dermatitis. Additionally, the European Medicines Agency's positive opinion on Jaypirca for chroni",
      "url": "https://finnhub.io/api/news?id=5420be4a870c13079b65675b3cdfd6ee173bf6bb8e2c85ee7f971434d15bdf85"
    },
    {
      "headline": "Amid Market Turmoil, Compelling Earnings Coming",
      "source": "SeekingAlpha",
      "datetime": 1741963200,
      "summary": "Investors looking for safe havens in a dangerous market. China EV players, FedEx and Micron earnings next week.",
      "url": "https://finnhub.io/api/news?id=872fca84d282f8da912d6da2335775c51c087e09e78f56152aafb7317d8cfeb5"
    },
    {
      "headline": "Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?",
      "source": "Yahoo",
      "datetime": 1741961322,
      "summary": "Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?",
      "url": "https://finnhub.io/api/news?id=1abe98a94a5099519afa678fad5327d6aa411241faf00be9fb4307183a812db2"
    },
    {
      "headline": "Anat Ashkenazi",
      "source": "MarketWatch",
      "datetime": 1741949280,
      "summary": "Anat Ashkenazi",
      "url": "https://finnhub.io/api/news?id=c45031300586367cc9629613300532a1bfd53bd1b327ba7e53a62cd7d6124531"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-13",
      "description": "xslF345X05/wk-form4_1741897046.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000091/xslF345X05/wk-form4_1741897046.xml"
    },
    {
      "form": "4",
      "date": "2025-03-04",
      "description": "xslF345X05/form4-03042025_040301.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000141588925006450/xslF345X05/form4-03042025_040301.xml"
    },
    {
      "form": "4",
      "date": "2025-03-03",
      "description": "xslF345X05/wk-form4_1741038785.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000083/xslF345X05/wk-form4_1741038785.xml"
    },
    {
      "form": "4",
      "date": "2025-03-03",
      "description": "xslF345X05/wk-form4_1741038712.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000081/xslF345X05/wk-form4_1741038712.xml"
    },
    {
      "form": "4",
      "date": "2025-02-26",
      "description": "xslF345X05/form4-02262025_040201.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000141588925005670/xslF345X05/form4-02262025_040201.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}